BreastArchives
ESMO 2025 and new therapies in breast cancer: does society always benefit?
Breast 1 min.
The ESMO 2025 Congress delivered practice-defining data across breast cancer. Key results included the first overall survival benefit for an adjuvant CDK4/6 inhibitor in high-risk HR+/HER2− early breast cancer and T-DXd established as standard in high-risk HER2+ disease. Novel antibody-drug conjugates...
Breast cancer masquerading as siliconoma: a cautionary tale
Breast 1 min.
Free silicone injections to the breast for augmentation purposes have been prohibited in many countries but late complications are still seen. These complications can range from swelling to pain and breast lumps. We report a case of delayed diagnosis of cancer due to the presence of silicone granulomata...
A reanalysis of a genome-wide association study on breast cancer in Asian populations using the SG10K_Health reference panel for imputation: a multi-Centre case-control analysis
Breast 1 min.
Genome-wide association studies (GWAS) have identified numerous genetic variants linked to breast cancer risk, but most discoveries come from European populations, limiting their applicability to other populations. Here, we show that the choice of genotype imputation reference panel, an essential step...
Antibody-drug conjugates in breast cancer
Breast 1 min.
Antibody-drug conjugates (ADCs) have garnered significant attention as an innovative therapeutic strategy in cancer treatment. The mechanism of action for ADCs involves the targeted delivery of antibodies to specific receptors, followed by the release of cytotoxic payloads directly into tumor cells....
